КАНЦЕРОПРЕВЕНЦИЯ ПРИ ЯЗВЕННОМ КОЛИТЕ
Аннотация
Об авторах
Д. В. ПодольскаяРоссия
М. В. Шапина
Россия
И. Л. Халиф
Россия
Список литературы
1. Белоусова Е. А. Воспалительные заболевания кишечника толстой кишки как предраковые состояния // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2002. - № 4 - С. 56-63.
2. Халиф, И.Л., Кашников В. Н., Гусев А. В., и др. Особенности возникновения и течение рака толстой кишки на фоне язвенного колита // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2012. - Т. 22. - № 1. - С. 57-63.
3. Шапошников А. В. Гепатоонкопревенция. Концепция и принципы реализации: пособие для врачей //М.: Форте принт - 2013. - 80 с.
4. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 10-14.
5. Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001; 120: 1356-1362
6. Azer SA. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur J Gastroenterol Hepatol. 2013; 25: 271-281
7. Bargen JA. Chronic ulcerative colitis associated with malignant disease. 1928. Dis Colon Rectum. 1994; 37: 727-730
8. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 44-48
9. Befrits R, Hammarberg C, Rubio C, et al. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum 1994; 37: 313-319
10. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009; 44: 46-55
11. Broome U., Lofberg R. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. - 1995. - 22: 1404-1408.
12. Bjarnason I, Macpherson AJ. Delivery, safety and efficacy of 5aminosalicylate preparation. Inflammopharmacology. 1993; 2: 277-287.
13. Choi PM and Zelig MP. Similarity of colorectal cancer of Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35: 950-954.
14. de Dombal FT. Ulcerative colitis. Epidemiology and aetiology, course and prognosis. Br Med J. 1971; 1: 649-650
15. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535
16. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323: 1228-1233
17. Fan W, Maoqing W, Wangyang C, et al. Relationship between the polymorphism of tumor necrosis factor-α-308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet. 2011; 19: 432-437
18. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105
19. Gyde S, Prior P, Dew MJ, et al. Mortality in ulcerative colitis. Gastroenterology. 1982; 83: 36-43
20. Hordijk M. L. Chivananda S. Risk of cancer in inflammatory Bowel Disease: why are the results in the reviewed literature so varied? / / Scand.J. Gastroenterol - 1989. Vol. 24. - P. 70-74
21. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012; 10: 639-645
22. Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143: 375-81
23. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004; 19: 287-293
24. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999; 116: 602-609
25. Kulaylat MN, Dayton MT. Ulcerative colitis and cancer. J Surg Oncol. 2010; 101: 706-712
26. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444-51.
27. Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet 1983; 2: 149-152
28. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol. 2005; 3: 1015-1021
29. Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analyses of Non-Referral Populations. Am J Gastroenterol. 2012; 107: 1298-1304.
30. Olsson R, Danielsson A, Järnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-1323
31. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994; 107: 117-120
32. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014; 345: 235-241.
33. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997; 39: 1-20
34. Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles. Fact or fiction? Drug Saf. 1994; 10(3): 183-95.
35. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002; 56: 48-54
36. Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-Aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentration, serum values, and urinary excretion. Gut 1990; 31: 1271-1276.
37. Subramanian V, Logan RF. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2011; 25:593-606
38. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009; 29: 2727-2737
39. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. AnnIntern Med. 2001; 134: 89-95
40. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011; 140: 1807-1816
41. Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006; 130: 1941-1949
42. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005; 100: 1345-1353
43. Winther KV, Jess T, Langholz E, et al. Longterm risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004; 2: 1088-95.
44. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 378-389
Рецензия
Для цитирования:
Подольская Д.В., Шапина М.В., Халиф И.Л. КАНЦЕРОПРЕВЕНЦИЯ ПРИ ЯЗВЕННОМ КОЛИТЕ. Экспериментальная и клиническая гастроэнтерология. 2016;(8):4-8.
For citation:
Podolskaya D.V., Shapina M.V., Khalif I.L. CANCERPREVENTIVE IN ULCERATIVE COLITIS. Experimental and Clinical Gastroenterology. 2016;(8):4-8. (In Russ.)